Double-Blind, Four Week Trial Of [S,S]-Reboxetine And Atomoxetine In Adults With Attention Deficit Hyperactivity Disorder.

Phase 2WithdrawnNCT00562055

Pfizer

Overview

This study will compare the safety and efficacy of \[S,S\]-reboxetine to atomoxetine in the treatment of adult patients with attention deficity-hyperactivity disorder.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Attention Deficit Hyperactivity Disorder

Interventions

AtomoxetineDRUG

PNU-165442G; [S,S]-reboxetineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Diagnosis of Attention Deficit Hyperactivity Disorder according to DSM-IV criteria. 2. Score of 24 or higher on the Adult ADHD Investigator Symptom Rating Scale 3. Score of 4 or higher on the Clinician Global Impression - Severity scale Exclusion Criteria: 1. Significant comorbid psychiatric diagnoses 2. Significant risk of suicidal or violent behavior

Outcomes

Primary Outcomes

Adult ADHD Investigator Symptom Rating Scale - Total Score

Time frame: 4 weeks

Secondary Outcomes

Adult ADHD Investigator Symptom Rating Scale - Inattention Subscale Score

Time frame: 4 weeks

Adult ADHD Investigator Symptom Rating Scale - Hyperactivity/Impulsivity Subscale Score

Time frame: 4 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.